This week, the ratings of 40 Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Biogen Inc. (BIIB) is having a tough week. The company’s rating falls from a C to a D. Biogen Inc. is a global biotechnology company that meets the needs of therapeutic care providers and recipients. For more information, get Portfolio Grader’s complete analysis of BIIB stock.

Alexion Pharmaceuticals, Inc. (ALXN) declines this week from a C to a D. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

This week, Intercept Pharmaceuticals, Inc.’s (ICPT) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

Agios Pharmaceuticals, Inc. (AGIO) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

Medivation, Inc. (MDVN) slips from a C to a D this week. Medivation, Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MDVN stock.

This week, Clovis Oncology, Inc. (CLVS) drops from a C to a D rating. Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLVS stock.

MacroGenics, Inc. (MGNX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of MGNX stock.

Slipping from a C to a D rating, Forward Pharma A/S Sponsored ADR (FWP) takes a hit this week. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of FWP stock.

This is a rough week for Esperion Therapeutics, Inc. (ESPR). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ESPR stock.

Applied Genetic Technologies Corp.’s (AGTC) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of AGTC stock.

Grifols, S.A. Sponsored ADR Class B (GRFS) gets weaker ratings this week as last week’s C drops to a D. Grifols, S.A. Sponsored ADR Class B develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. For more information, get Portfolio Grader’s complete analysis of GRFS stock.

Coherus BioSciences, Inc. (CHRS) slips from a C to a D this week. Coherus BioSciences, Inc. operates chains of women’s large-size specialty apparel stores and retails apparel, accessories, footwear, and gifts through catalogs. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

Immune Design Corp’s (IMDZ) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

OncoMed Pharmaceuticals, Inc. (OMED) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OMED stock.

Ironwood Pharmaceuticals, Inc. Class A (IRWD) is having a tough week. The company’s rating falls from a D to a F. Ironwood Pharmaceuticals, Inc. Class A discovers, develops, manufactures, and commercializes marketed drugs. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of IRWD stock.

Epizyme, Inc. (EPZM) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

TG Therapeutics, Inc. (TGTX) experiences a ratings drop this week, going from last week’s C to a D. TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TGTX stock.

OPKO Health, Inc. (OPK) declines this week from a C to a D. OPKO Health, Inc. is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. For more information, get Portfolio Grader’s complete analysis of OPK stock.

This week, Merrimack Pharmaceuticals, Inc. (MACK) drops from a C to a D rating. Merrimack Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of MACK stock.

Slipping from a D to a F rating, Avalanche Biotechnologies Inc (AAVL) takes a hit this week. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AAVL stock.

This is a rough week for ProQR Therapeutics N.V. (PRQR). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRQR stock.

This week, Sorrento Therapeutics, Inc.’s (SRNE) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SRNE stock.

This week, Stemline Therapeutics, Inc. (STML) drops from a D to a F rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of STML stock.

Spectrum Pharmaceuticals, Inc. (SPPI) declines this week from a C to a D. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company also gets F’s in sales growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of SPPI stock.

CareDx, Inc. (CDNA) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in operating margin growth, earnings growth, earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CDNA stock.

Aldeyra Therapeutics, Inc. (ALDX) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

This is a rough week for GlycoMimetics, Inc. (GLYC). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

Agenus Inc. (AGEN) earns a D this week, moving down from last week’s grade of C. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

Slipping from a C to a D rating, Genocea Biosciences, Inc. (GNCA) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

Capricor Therapeutics, Inc. (CAPR) slips from a C to a D this week. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CAPR stock.

Heat Biologics, Inc.’s (HTBX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of HTBX stock.

BioTime, Inc. (BTX) experiences a ratings drop this week, going from last week’s C to a D. BioTime, Inc. is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BTX stock.

This week, Fate Therapeutics, Inc.’s (FATE) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FATE stock.

Actinium Pharmaceuticals, Inc. (ATNM) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ATNM stock.

Catalyst Pharmaceuticals, Inc. (CPRX) earns a D this week, moving down from last week’s grade of C. Catalyst Pharmaceuticals, Inc. focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of CPRX stock.

This is a rough week for Conatus Pharmaceuticals Inc. (CNAT). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

Arena Pharmaceuticals, Inc.’s (ARNA) rating weakens this week, dropping to a F versus last week’s D. Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies offering medical advances and new options for patients. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARNA stock.

MEI Pharma, Inc. (MEIP) slips from a C to a D this week. MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MEIP stock.

This week, Celladon Corporation’s (CLDN) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

This week, Macrocure Ltd. (MCUR) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MCUR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.